Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Views & Analysis
Health-Prize-Technologies_banner_570x320

Non-adherence: pharma’s final financial frontier

No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D